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Expression of glycolipid blood group antigens in single human kidneys:
Change in antigen expression of rejected ABO incompatible kidney grafts.
Total neutral glycolipid fractions were separated into molecular species
on thin-layer chromatography plates and detected by immunostaining
with monoclonal anti-blood group antibodies. Blood group A antigens
based on type 1, 2, 3 and 4 carbohydrate core saccharides were present
in kidneys of A1 and A1B individuals. Blood group A2 individuals
expressed only small amounts of A antigen compared to A1 individuals
especially of the type 3 and 4 compounds. Kidneys from non-secretor
individuals contained less A antigen compared to secretor individuals,
and in both groups a variation in the antigen expression between single
individuals was noted. Blood group A type 2 and 3 (which is an
extension of A type 2) antigens were present both as basic 6 and 9 sugar
structures as well as extended saccharide chains migrating in the 8 to II
sugar interval. In contrast, the type 1 chain based A and Lewis antigens
were only present as their basic 5 to 7 sugar chains, and no elongated
structures were found. Four cases of A2 kidneys initially transplanted
into 0 recipients and removed after 5, 12, 21 days and 4 years,
respectively, were also analyzed. Two of these kidneys, originating
from the same donor, showed a difference in A antigen expression. The
kidney functioning for four years (lost due to chronic rejection) com-
pletely lacked X antigen with five sugar residues (present in all other
individuals) and contained a large amount of A antigens. This shows
that the expression of antigens in an incompatible transplated organ can
be changed post-transplantation, and that the organ can function even if
large amounts of incompatible antigens are present.
The chemical structures of the blood group ABH antigens
and the structurally related Lewis and X/Y antigens were
initially elucidated on milk oligosaccharides, ovarian cyst gly-
coproteins and erythrocyte glycolipids [1—3]. The structural
complexity of these antigens has increased considerably and,
for example, at least eleven different blood group A antigens
have been identified so far [4]. The expression of these antigens
in tissues and cells is controlled by the ABO, H, Se, P, Le and
X genes [2, 5, 6], but also other still unknown factors are
involved, as exemplified by the difference in expression within
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organs and cells of a single individual [5, 7—9]. The blood group
ABH, Lewis and X/Y antigens therefore have an individual,
tissue and cell specific distribution [8] and are present on
virtually every cell in the body. Phylogenetic studies have
shown that these antigens appear earlier in evolution in ecto-
dermal or endodermal tissues and cells compared to mesenchy-
mal hematopoietic cells [5], Therefore the term "histo-blood
group" antigens have been proposed for these carbohydrate
antigens [6].
The ABH and related carbohydrate antigens are located on
the cell surface and are proposed to take part in cell-cell
communication phenomena [10]. They are also targets for
antibodies, which was shown in studies of ABO incompatible
transfusion [11] and organ transplantations [12] where both
antigen and individual specific antibody responses were pro-
duced in the recipients challenged with incompatible blood
group A antigen. Transplantation of kidneys involving major
ABO incompatibilities have been performed with good results
using an aggressive immunosupression regimen including
spleenectomy [13, 14], and kidneys from A2 donors can be
transplanted to 0 recipients using standard immunosuppression
[15]. We have described a difference in the expression of A
antigens in human kidney from single individuals using a
monoclonal anti-A antibody reacting with all A determinants
[15, 16]. In this paper the expression of structurally different
glycolipid based A, Lewis and X/Y antigens in several human
kidneys from single individuals are analyzed by use of a panel of
specific monoclonal antibodies. In addition, blood group A2
kidneys transplanted into 0 recipients and later removed after
various time periods were also analyzed.
Methods
Kidney specimens
The kidney specimens were obtained from the transplanta-
tion unit, Sahlgren's Hospital. The kidneys were discarded for
lack of suitable recipients or for technical reasons. The kidneys
were perfused with kidney storage solution, kept cool and
sterile. Blood group typing of the donors' erythrocytes was
performed at the blood bank by standard procedures. Secretor
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No A subtyping
performed
Kidney transplanted to
a blood group 0
recipient and
removed on day 21
[15]
Kidney transplanted to
a blood group 0
recipient and
removed on day 5
due to irreversible
vascular rejection,
case 11:2 in [12]
Same donor as case
13. Kidney
transplanted into
another group 0
recipient and
removed on day 12,
case 11:1 in [12].
Kidney transplanted to
blood group 0
recipient. Removed
after 4 years due to
chronic rejection.
No Lewis typing
performed.
A Le(a—b+) individuals are regarded as secretors and Le (a+b—) as
non-secretorsb This donor was by printing error incorrectly assigned Le(a—b+) in
[12]
status was deduced from the Lewis typing. In some cases blood
group A2 kidneys initially transplanted to blood group 0 recip-
ients and removed after different time periods were obtained
and analyzed. The blood group types and relevant clinical data
for each kidney specimen are listed in Table 1.
Glycolipid preparation
Total neutral glycosphingolipid fractions were prepared from
the lyophilized kidney tissues as described in detail [171. The
average amount of total neutral glycolipid fractions isolated
from each non-transplanted kidney was 118 mg (range 61 to 195
mg) corresponding to 5.5 mg per g dry tissue weight (range 4.7
to 7.9 mg). The values for the transplanted and rejected kidneys
were 272 mg (188 to 334 mg) corresponding to 5.6 mg per g dry
tissue weight (3.7 to 9.4 mg).
Thin-layer chromatography and immunostaining of the plates
Thin-layer chromatography was performed on HPTLC-alu-
minium-plates (Merck, Darmstadt, Germany) and developed in
chloroform: methanol: water, 60:35:8 (vol :vol:vol). Detection
was accomplished by a chemical reagent, anisaldehyde [171 or
by autoradiography after incubating the plate with monoclonal
anti-blood group antibodies, followed by '251-labeled secondary
antibody using a modification of the method by Magnani et al [8,
12, 18].
Monoclonal antibodies and glycolipid reference samples
The mouse monoclonal antibodies, reference glycolipid sam-
ples and glycolipid short hand nomenclature used are described
in Tables 2 and 3, respectively.
Results
The total non-acid glycolipid pattern of the human kidneys
were very similar when the plates were stained with a chemical
reagent [9, 15, 16] (not shown). The major components present
had 1 to 4 sugar residues and small amounts of 5 sugar
components are also seen [9, 15, 16]. The amount of complex
blood group type glycolipids was estimated to about 1% of the
total glycolipid fraction [9], and were not seen on the plate using
a chemical reagent but were detected by immunostaining the
plates with antibodies [15, 16], as shown in Figure 1. The
staining of glycolipid antigens on thin-layer plates by biological
reagents such as monoclonal antibodies, lectins, toxins and
bacteria/virus is a qualitative and a "semiquantitative" tech-
nique for antigen identification [11, 12, 29, 30]. Therefore, the
results were presented as autoradiograms (Fig. 1) and not as
numeric figures. The anti-A antibody used in Figure 1A recog-
nized the terminal A trisaccharide and reacted with all struc-
tural variants of A antigens [16]. This antibody revealed a very
complex pattern of A structures in the kidneys of A1 individuals
(lanes 1 to 9) while the A2 individuals stained very faintly (lane
10) or not at all (lane 11). In addition to the components
migrating as the reference compounds with 6 to 9 sugar resi-
dues, several slow moving components with about 10 to 12
sugar residues were seen in some of the A1 individuals. The A2
kidneys which had been transplanted into 0 recipients were all
negative or faintly stained (lanes 12 to 14), except for one case
(lane 15). The antibodies AH-21 and HH-4 are specific for A
monofucosyl structures based on type 1 and 2 core chain
structures, respectively. The AH-21 antibody stained a 6 sugar
component present in all A1 kidneys and in some of the A2
kidneys (Fig. 1B) while the HH-4 antibody stained components
in the 8-9 sugar region in some of the A1 kidneys in addition to
the major staining present in the 6 sugar region of all A1
individuals (Fig. lC). The A2 kidneys transplanted into 0
recipients were all stained in various degrees with the A type 2
antibody (Fig. 1C). The TH-1 antibody, specific for A type 3
chain compounds (Fig. 1D) reacted with a 9 sugar structure
present in the A1 kidneys but was absent in the A2 kidneys
except for a very faint staining in one case (lane 10). The type
3 chain compound in the kidneys migrated just below the A-9-3
reference compound from human erythrocytes. This difference
Table 1. Blood group type and relevant clinical data for the kidney
specimens analyzed in the immunostaining experiments
Clinical data and
comments
Lewis typing uncertain
due to old RBC
sample
No Lewis typing
performed
Case
(lanes in
Fig. 1)
2
3
4
5
6
7
8
9
10
11
12
13
14
15
Blood group
phenotype of
the donor
erythrocytes
A1LC(a_b+)a
A1Le(a—b+)
A1Le(a—b+)
A1
A1Le(a—b+)
A1Le(a+b—)
A1(Le(a+b—)
AB Le(a—b+)
A1B Le(a—b+)
A2
A2Le(a+b—)
A2Le(a—b—)
A2Le(a+b—)"
A2Le(a+b—)"
A2
No Lewis typing
performed
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Table 2. Antigen specificity of the mouse monoclonal antibodies used in the immunostaining experiments
Antibodya Fig. I Code no. Specificity Reference
Anti-A all variants A A581 Dakopatts Terminal A trisaccharide [16]
Anti-A type 1 B AH-21 A type 1, monofucosyl [19]
Anti-A type 2 C HH-4 A type 2, monofucosyl [4]
Anti-A type 3 D TH-l A type 3 [20]
Anti-A type 3 and 4 E HH-5 A type 3 and 4 [4]
Anti.ALeb F HH-3 A type 1, difucosyl [21)
AntiLea G XALA Chembiomed Lea terminal
AntiLet H 9ALB Chembiomed Leb and H type I terminalsb
Anti-X I SH-l X terminalsc
Anti-Y J AH-6 Y terminals [21]
Anti-B — A582 Dakopatts Terminal B trisaccharide'
a The antibodies were culture supernatants containing 10 to 30 g Ig/mI
b This antibody was shown to cross-react with the blood group H type I chain compounds
Singhal A., Nance S., Hakomori S., unpublished observations
d Reacts weakly with difucosylated structures
Table 3. Reference glycolipid samples used in the immunostaining experiments
Short hand
designationa Glycolipid structure Tissue source Reference
E Total non-acid glycolipid fraction Erythrocytes of a human [22]
A1Le(a—b+) secretor individual
A-6-1 GalNAcal-3(Fucal-2)Gall3l-3GlcNAcI3l-3GalI3l-4Glcf3l-lCer Human meconium [23]
A-6-2 GalNAcal-3(Fucal-2)Gal/3l-4GlcNAc/31-3Gall-4Glcfll-lCer Dog small intestine [24]
A-7-l GalNAcal-3(Fucal-2)Gall-3(Fuca1-4)GlcNAcl-3Gal/31-4Glc/3l- ICer Human meconium [23]
A-7-4 GalNAcal-3(Fucal-2)Galj3l-3GaINAc/3l-3Galal-4Gal/3l-4Glc/31-lCer Human kidney [25]
A-9-3 GalNAcal-3(Fuca1-2)Galpl-3GalNAcal-3(Fucal-2)GalI31-4GlcNAcl-3 Human erythrocytes [4, 26]
Ga1131-4GlcI3l-lCer
Lea5 Gal/31-3(Fucal-4)GIcNAcI3I-3Gal/3l-4Glc/3l- ICer Human small intestine
Leb6 Fucal-2GalI3l-3(Fucal-4)GlcNAc/31-3Galf3l-4GlcI3l- ICer Human small intestine
[27]
[7]
X-5 Galf3l-4(Fucal-3)GlcNAc/31-3Gal/3l-4Glc/3l-lCer Dog small intestine [28]
Y-6 Fucal-2Gal/3l-4(Fucal-3)GlcNAcj3l-3Galf3l-4Glc/31-lCer Dog small intestine [28]
a For blood group glycolipids, the letter indicates blood group determinant, the first numeral the number of sugar residues, and the second
numeral the type of carbohydrate chain
in mobility was most likely due to a more hydroxylated ceram-
ide [31] than to a different carbohydrate structure. The HH-5
antibody recognizing both type 3 and 4 chain A compounds
reacted with several bands in the A1 kidneys of which the A-7-4
and A-9-3 were the dominating compounds (Fig. 1E). For the
A2 kidneys a weaker and more variable staining was seen. The
relatively weak staining of A type 3 and 4 compounds in Figure
lA compared to Figure IE was due to a weaker reactivity of
these antigens with general anti-A antibodies recognizing the
terminal A trisaccharide [20]. Blood group A difucosyl type I
chain (ALeb) compounds with 7 sugar residues were present in
all A1 kidneys (Fig. iF) but the staining of A1Le(a+b—)
individuals was weaker (lanes 6 and 7) and the A2 kidneys (lanes
10 and 11) were negative while the transplanted kidneys (lanes
12 to 15) showed a variable staining.
The anti-B antibody reacted only with the blood group AB
kidneys (cases 8 and 9) as expected (not shown). The staining
was present only in the 6 sugar region of the chromatogram, in
contrast to blood group B kidneys obtained at autopsy [32]
which also contained blood group B compounds in the 7-8 sugar
interval, most probably originating from erythi-ocytes trapped
in the organ. The antiLea antibody stained a five sugar com-
ponent present in variable amounts in all A1 kidneys and in
some of the transplanted A2 kidneys (Fig. 1G). Leb antigens
with 6 sugar residues were present in a similar manner (Fig.
lH). In some cases (for example, 7) Leb antigens were found in
a serological Leb negative individual, a phenomenon reported
before for human meconium [33] and small intestine [8].
The X antigens are the type 2 chain isomers of the Lea
antigens, and these were detected by the SH-1 antibody react-
ing with the terminal X trisaccharide determinant. This anti-
body reacted with a 5 sugar component present in all kidneys
(Fig. LI) except case 15. The X-5 glycolipid has been structur-
ally identified as one of two components present in the 5 sugar
band detected by the chemical staining of the plates [9, 321. In
the transplanted kidneys several bands were stained (lanes 12 to
15) migrating below the 5 sugar component. These are probably
elongated repetitive X structures originating from white blood
cells trapped in the rejected organs, since granulocytes have
been shown to contain large amounts of these components [34].
A similar distribution for the corresponding Y antigens (type 2
chain isomers of Leb) was also found (Fig. U) with only trace
amounts of a 6 sugar component in some of the nontransplanted
kidneys, while several slow moving bands were seen in the
transplanted cases (lanes 12 to 15).
Discussion
The kidneys analyzed are a unique human tissue collection
obtained during a ten year period. Since the kidneys were
A A all types
V
S S S a S a — a a
— r — — — —
a2345 6 7892E %::11o1112131415:E
B A type 1
ss
A-6-1- 1 10 11 12 13 14 15
C A type 2
4-6-21 2 3 4 5 6 7 6 9A6-2E A-6-21 1011 121314 I5A-6-2E
P Atype3
a aa
—I
A-9-3 1 2 3 4 5 6 7 6 9 A-9-3 E 1 10 11 12 13 14 15 E
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Fig. 1. Autoradiograms of thin-layer plates immunostained with different monoclonal anti-blood group antibodies. Total neutral glycosphin-
golipid fractions isolated from single human kidneys (lanes ito 15), erythrocytes and appropriate pure reference glycolipids were applied on each
plate. Blood group status of the tissue donors, the structures and shorthand designation of the reference compounds are listed in Tables I and 3,
respectively. The kidney fractions were subgrouped into blood group A1 (left column, lanes I to 9) and A2 (right column, lanes 10 to 15), of which
cases 12 to 15 were A2 kidneys transplanted to blood group 0 individuals and removed after various time periods (Table I). The monoclonal
antibodies used were: A, A581; B, AH-21; C, HH-4; D, TH-I, E, HH-5; F, HH-3; G; XALA; H, 9ALB; I, SH-l; and J, AH-6. The specificity of
the monoclonal antibodies is given in Table 2. The amount of glycolipid substance applied was about 40 jsg of the kidney fractions, 20 jig of the
erythrocyte fraction and 0.2 jig of each pure reference compound. The chemical staining of plates (not shown) revealed no differences between
the individuals [15, 16], since the blood group components make up only about 1% of the glycolipis and are not detected by chemical staining [9].
Arrows indicate sample origin.
E Atype3and4
A-7-1 1 2 3 4 5 6 7 8 9A-7-1 E A-7-1 1 10 11 12 13 14 15
Fig. 1. Continued
intended for transplantation, they were perfused with salt
solution, removing plasma and blood cells, and thereafter
stored sterile at low temperature. For most of the cases an
extended blood group typing (A1/A2 and Lewis) of the donor
erythrocytes was performed, but in some of the cases this was
not possible due to lack of blood samples. From the Lewis
erythrocyte phenotype, the secretor status was be concluded
where Le(a+b—) individuals are regarded as non-secretors and
Le(a—b+) as secretors.
The expression of A antigens in the kidneys is very complex
with both quantitative and qualitative differences between the
individuals. Comparing the A1, (Fig. lÀ through F, lanes I to 9)
and A2 (lanes 10 to 11) kidneys, the A1 kidneys contain larger
amounts and have a more complex expression of the A antigens
than the A2 kidneys. However, within the A1 group consider-
able differences are seen of which some, but not all, can be
related to the secretor (lanes 1 to 5) and non-secretor (lanes 6 to
7) status. The A type 2 and A type 3 (which is an extension of
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type 2; Table 3) antigens are present both as the basic A-6-2 and
A-9-3 structures and with extended saccharide chains migrating
in the 8 to 11 sugar interval (Fig. lC and E). In contrast, the
type 1 chain compounds are only present as their basic struc-
tures with five (Lea5), six (A-6-1, Le'-6) and seven (A-7-1)
sugar residues. The only extended type 1 chain core saccharide
identified so far in human tissues is a repetitive Lea structure
with eight sugar residues found in human meconium [35] and
small intestine [36] (Holgersson J, Jovall p-A, Karisson K-A,
Breimer ME, unpublished observations). A blood group A
octaglycosylceramide with a repetitive type 1 chain core sac-
charide has been found in rat small intestine [37]. For the type
2 chain antigens X and Y, only 5 and 6 sugar compounds,
respectively, were identified in the non-transplanted kidneys
(Fig. 11 and J, lanes 1 to 11) but using another anti-X-antibody
a 7 sugar component was seen in some of the cases analyzed at
that time (38].
Immunohistochemical studies have shown that the ABH,
Lewis and related antigens are specifically distributed in the
human kidney. The ABH antigens in the vascular epithelium
and the X antigens in the proximal convoluted tubules and
descending limb of the loop of Henle are expressed independent
of the secretor gene, while the ABH and Lea/Leb antigens in the
distal tubules and collecting tubules are secretor dependent
[39—41]. The expression of different blood group antigens in
certain tissues and cells has also been correlated to the embry-
ological origin of the tissues [5]. Blood group glycolipids are
also known to have a tissue and cell specific distribution [7—9]
and a correlation between the number of hydroxyl groups in the
ceramide part and the distribution in different cells has been
documented [7, 8, 42]. From the thin-layer mobility and mass
spectrometry analysis [9] (Holgersson, J, Jovall p-A, Karlsson
K-A, Breimer ME, unpublished observations) the A type 2
chain structures contain less hydroxylated ceramides compared
to the type 3 chain structure. This may indicate a different
cellular distribution of these compounds, that is, type 2 chain
compound in the vascular endothelium and type 3 structures in
the distal and collecting tubules. This also fits with the secretor
dependent expression of A antigens in the distal and collecting
tubules since the amount of A type 3 chain structures are low in
non-secretors (Fig. lD and E, lanes 6 and 7).
From the results presented here, it can be concluded that the
expression of the structurally different A antigens in the human
kidney cannot be established from routine blood group typing of
the donor erythrocytes, which is the major donor/recipient
selection criterion in organ transplantation. The possibility to
cross the ABO barriers in kidney transplantation has been
shown both by using immunologic modifications of the recipi-
ents [13, 14] and using standard immunosuppression regimens
[15]. In certain situations, the possibility to cross the ABO
barriers may be necessary, and in these cases a more detailed
knowledge of the antigen expression in the organ to be trans-
planted would be of benefit to select a "low antigenic" organ,
such as cases 6, 10 and 11 in Figure 1. The use of a panel of
monoclonal anti-blood group antibodies for serological tests or
immunohistological studies of an organ biopsy may be the
solution for this problem.
An interesting finding is the difference in blood group glyco-
lipid antigen expression in the two blood group A2 kidneys
obtained from the same donor and transplanted into two differ-
ent blood group 0 recipients (cases 13 and 14 in Fig. 1
corresponding to cases 11:1 and 11:2 in ref. 11). Kidney number
13 was removed on day 5 post-transplantation and case 14 on
day 12. Kidney 13 was probably not circulated for more than
one to two days. Several reasons for the low amounts of A
antigens present in case 14 seem possible. Destruction of the
antigens by the immune system would result in less antigen
expression in the kidney lost after two weeks compared to the
one removed after five days. Another possibility would be an
influence on the expression by cytokines, for instance gamma
interferon, which has been shown under experimental condi-
tions to reduce the expression of neutral glycospingolipids, like
globoside, on endothelial cell surfaces [43]. Still another possi-
bility could be the presence of glycosyltransferase inhibitors of
an antibody nature being produced in the recipient, influencing
the activity of the A-transferase and thus reducing the A antigen
expression. Such glycosyltransferase inhibitors have been
found in ABO-incompatible bone marrow transplantations [44,
45], in liver transplantation [46] and in renal transplantation
[47]. The sera of patients 13 and 14 obtained four to five weeks
after transplantation were investigated for inhibitory activity
against A-glycosyltransferase, but no such inhibitor was found
(cases 9 and 10 in ref. 47). The reduced expression of antigens
in case 14 compared to case 13 as investigated by thin-layer
chromatography was compared with expression of A antigens
in paraffin-embedded tissue sections by immunofluorescence.
No major difference in expression could be detected by this
technique (Rafael Oriol, personal communication). This does
not, however, rule out a quantitative difference since the tissue
sections only reveal the situation in a small areal of the organ.
We have recently obtained two kidneys from one single donor
of blood group A1Le(a—b+) and prepared the glycolipid frac-
tions from each kidney separately. Immunostaining of the
glycolipid fractions with anti-A antibodies revealed a blood
group pattern similar to cases 1 and 3, and no qualitative or
quantitative difference between the two kidneys was found
(data not shown). Therefore the change in glycolipid A antigen
expression in the transplanted pair of kidneys has occurred
post-transplantation. The large amount of extended X antigens
found in the transplanted kidneys (Fig. 11, lanes 12 to 15) most
probably originates from white blood cells in the rejected
organs since complex X glycolipid structures are major compo-
nents in human granulocytes [34]. The origin of the extended Y
antigens present in the transplanted kidneys (Fig. 1J, lanes 12 to
15) may be explained in a similar way, but to our knowledge Y
antigens have so far not been found in plasma or the various
blood cell components.
The complete absence of the X-5 compound in the A2 kidney
transplanted into an 0 recipient which functioned for four years
(Fig. 1!, lane 15) is of particular interest. Since the X-5 antigen
is present in all the non-transplanted kidneys (cases I to II) it
originates from the kidney tissue itself. Immunofluorescence
studies have shown that the X antigen determinant is restricted
to the proximal convoluted tubules and some single granulo-
cytes present in the interstitial compartment [48]. The absence
of the X-5 antigen in case 15 may be due to either lack of the
antigen before transplantation or a change in the expression
occurring post-transplantation as discussed above. Several dis-
tinctly different a-3-fucosyltransferase activities have been
found in human tissues [5, 49, 50]. No individual lacking the
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myeloid type of enzyme has been described so far, and only 11
individuals lacking the plasma enzyme have been identified and
all were found to be Lewis negative, Le(a—b—) [48, 49]. The
low frequency of individuals lacking the a-3-fucosyltransferase,
and the fact that the kidney of case 15 contains ALeb, Lea and
Leb antigens (Fig. iF, G and H) makes it unlikely that the X-5
antigen was absent in the kidney prior to transplantation. If the
absence of X-5 antigens is caused by a lack of enzyme activity,
this is most probably due to a lack of the al-3 fucosyltrans-
ferase since the presence of A-6-2 compounds (Fig. 1C, lane 15)
shows that elongation of the type 2 chain precursor (neolac-
totetra) is possible. However, it was not possible to test for this
since no fresh tissue from that case was available. The other A2
kidneys transplanted into 0 recipients (cases 12 to 14) all
contain the X-5 compound, suggesting that the disappearance of
this component occurred later in the post-transplantation pe-
riod.
The problem with hyperacute rejection of allografts caused
by anti-ABH or anti-HLA class I antibodies has been overcome
by removing the offending antibodies prior to the transplanta-
tion, and thereafter maintaining antibody depletion for a finite
period [13, 51]. After this period the engrafted organ would
continue to function despite the return of the antidonor anti-
bodies and the presence of an intact complement system. This
phenomenon has recently been referred to as "accomodation"
[52, 53]. In our study, case 15 may be an example of this
phenomenon. This blood group A2 kidney transplanted into an
o recipient functioned for four years and was lost due to
chronic rejection. The removed kidney contained large amounts
of blood group A antigens (Fig. 1A to C, and E, lane 15). At the
time of removal of this ABO incompatible kidney, the recipient
anti-A agglutinin titer against A1 erythrocytes was 1:16 and the
indirect antiglobulin titer 1:32. This shows that "accomoda-
tion" can occur also when the incompatible antigens are
present in the organ.
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